Bench to bedside: The development of rapamycin and its application to stent restenosis

Circulation

Volumn 104, Issue 8, 2001, Pages 852-855

  Marx, Steven O ^a   Marks, Andrew R ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Editorials; Restenosis; Signal transduction; Stents

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; DRUG USE; EDITORIAL; HUMAN; HUMAN CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; STENT; VASCULAR SMOOTH MUSCLE;

EID: 0035928843     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.104.8.852     Document Type: Editorial

References (42)

1. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients
2. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months
3. Prevention of coronary restenosis: The evolving evidence base for radiation therapy
4. Gene therapy for vascular smooth muscle cell proliferation after arterial injury
5. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
6. Catheter-based radiotherapy to inhibit restenosis after coronary stenting
7. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent anticoagulation restenosis study investigators
8. Late coronary occlusion after intracoronary brachytherapy
9. Late thrombosis after radiation: Sitting on a time bomb
10. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
11. Rapamycin inhibits vascular smooth muscle cell migration
12. Rapamycin (AY-22,989), a new antifungal antibiotic. I: Toxoneme of the producing streptomycete and isolation of the active principle
13. Rapamycin (AY-22,989), a new anti-fungal antibiotic. II. Fermentation, isolation and characterization
14. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line
15. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury
16. Rapamycin (sirolimus) inhibits vascular smooth muscle cell DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells
17. Rapamycin resistance tied to defective regulation of p27Kipl
18. Attacking heart disease with novel molecular tools
19. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by rapamycin
20. Kipl in vascular smooth muscle cell migration
21. Cellular functions of immunophilins
22. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast
23. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an inmmnophilin and either FK506 or rapamycin
24. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin
25. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with gl/s-phase growth arrest in T lymphocytes
26. Chemistry and biology of the immunophilins and their immunosuppressive ligands
27. Interleukin-2-mediated elimination of the p27kipl cyclin-dependent kinase inhibitor prevented by rapamycin
28. p27kipl, a cyclin-Cdk inhibitor, links transfoming growth factor-β and contact inhibition to cell cycle arrest
29. kipl
30. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase
31. cAMP- and rapamycinsensitive regulation of the association of eukaryotic initiation factor 4E and the translational repressor PHAS-I in aortic smooth muscle cells
32. Cell cycle progression and proliferation despite 4BP-I dephosphorylation
33. ink4 on vascular smooth muscle cell proliferation
34. Rapamycin in transplantation: A review of the evidence
35. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study: The Rapamune US Study Group
36. Lack of neotintimal proliferation after implantation of sirolimus-coated stents in human coronary arteries
37. Edge restenosis after implantation of high activity (32)P radioactive β-emitting stents
38. Mid- (4 month) and long-term (1 year) QCA and three dimensional IVUS followup after implantation of sirolimus-coated stent in human coronary arteries
39. Comparison between sirolimuscoated and noncoated stent implantation in human coronary arteries
40. Incidence and progression of transplant coronary artery disease over 1 year: Results of a multicenter trial with use of intravascular ultrasound
41. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease
42. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model